Article Type
Article
Changed
Thu, 04/24/2025 - 20:15
Display Headline

Lung Cancer: Mortality Trends in Veterans and New Treatments

Author(s)
Millie Das, MD

Click to view more from Cancer Data Trends 2025.

References
  1. Tehzeeb J, Mahmood F, Gemoets D, Azem A, Mehdi SA. Epidemiology and survival
    trends of lung carcinoids in the veteran population. J Clin Oncol. 2023;41:e21049.
    doi:10.1200/JCO.2023.41.16_suppl.e21049
  2. Moghanaki D, Taylor J, Bryant AK, et al. Lung Cancer Survival Trends in the Veterans
    Health Administration. Clin Lung Cancer. 2024;25(3):225-232. doi:10.1016/j.
    cllc.2024.02.009
  3. Jalal SI, Guo A, Ahmed S, Kelley MJ. Analysis of actionable genetic alterations in
    lung carcinoma from the VA National Precision Oncology Program. Semin Oncol.
    2022;49(3-4):265-274. doi:10.1053/j.seminoncol.2022.06.014
  4. Cascone T, Awad MM, Spicer JD, et al; for the CheckMate 77T Investigators.
    Perioperative Nivolumab in Resectable Lung Cancer. N Engl J Med.
    2024;390(19):1756-1769. doi:10.1056/NEJMoa2311926
  5. Wakelee H, Liberman M, Kato T, et al; for the KEYNOTE-671 Investigators.
    Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer. N Engl J
    Med. 2023;389(6):491-503. doi:10.1056/NEJMoa2302983
  6. Heymach JV, Harpole D, Mitsudomi T, et al; for the AEGEAN Investigators.
    Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. N Engl J
    Med. 2023;389(18):1672-1684. doi:10.1056/NEJMoa2304875
  7. Duncan FC, Al Nasrallah N, Nephew L, et al. Racial disparities in staging, treatment,
    and mortality in non-small cell lung cancer. Transl Lung Cancer Res. 2024;13(1):76-
    94. doi:10.21037/tlcr-23-407
Author and Disclosure Information

Mille Das, MD
Clinical Professor
Department of Medicine/Oncology 
Stanford University 
Stanford, California;
Chief, Oncology 
Department of Medicine 
VA Palo Alto Health Care System
Palo Alto, California 

 

Disclosures: Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Sanofi/ Genzyme; Regeneron; Janssen; Astra Zeneca; Gilead; Bristol Myer Squibb; Catalyst Pharmaceuticals; Guardant; Novocure; AbbVie; Daiichi Sankyo. 
Received research grant from: Merck; Genentech; CellSight; Novartis; Varian. 
Received income in an amount equal to or greater than $250 from: Plexus; IDEO; Springer; Medical Educator Consortium; Dedham Group; DAVA Oncology; MJH Healthcare Holdings; Targeted Oncology; OncLive; ANCO; Aptitude Health; MashUp Media; Med Learning Group; Curio; Triptych Health; American Cancer Society.

Publications
Federal Practitioner
Topics
Oncology
Lung Cancer
Author(s)
Millie Das, MD
Author(s)
Millie Das, MD
Author and Disclosure Information

Mille Das, MD
Clinical Professor
Department of Medicine/Oncology 
Stanford University 
Stanford, California;
Chief, Oncology 
Department of Medicine 
VA Palo Alto Health Care System
Palo Alto, California 

 

Disclosures: Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Sanofi/ Genzyme; Regeneron; Janssen; Astra Zeneca; Gilead; Bristol Myer Squibb; Catalyst Pharmaceuticals; Guardant; Novocure; AbbVie; Daiichi Sankyo. 
Received research grant from: Merck; Genentech; CellSight; Novartis; Varian. 
Received income in an amount equal to or greater than $250 from: Plexus; IDEO; Springer; Medical Educator Consortium; Dedham Group; DAVA Oncology; MJH Healthcare Holdings; Targeted Oncology; OncLive; ANCO; Aptitude Health; MashUp Media; Med Learning Group; Curio; Triptych Health; American Cancer Society.

Author and Disclosure Information

Mille Das, MD
Clinical Professor
Department of Medicine/Oncology 
Stanford University 
Stanford, California;
Chief, Oncology 
Department of Medicine 
VA Palo Alto Health Care System
Palo Alto, California 

 

Disclosures: Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Sanofi/ Genzyme; Regeneron; Janssen; Astra Zeneca; Gilead; Bristol Myer Squibb; Catalyst Pharmaceuticals; Guardant; Novocure; AbbVie; Daiichi Sankyo. 
Received research grant from: Merck; Genentech; CellSight; Novartis; Varian. 
Received income in an amount equal to or greater than $250 from: Plexus; IDEO; Springer; Medical Educator Consortium; Dedham Group; DAVA Oncology; MJH Healthcare Holdings; Targeted Oncology; OncLive; ANCO; Aptitude Health; MashUp Media; Med Learning Group; Curio; Triptych Health; American Cancer Society.

Click to view more from Cancer Data Trends 2025.

Click to view more from Cancer Data Trends 2025.

References
  1. Tehzeeb J, Mahmood F, Gemoets D, Azem A, Mehdi SA. Epidemiology and survival
    trends of lung carcinoids in the veteran population. J Clin Oncol. 2023;41:e21049.
    doi:10.1200/JCO.2023.41.16_suppl.e21049
  2. Moghanaki D, Taylor J, Bryant AK, et al. Lung Cancer Survival Trends in the Veterans
    Health Administration. Clin Lung Cancer. 2024;25(3):225-232. doi:10.1016/j.
    cllc.2024.02.009
  3. Jalal SI, Guo A, Ahmed S, Kelley MJ. Analysis of actionable genetic alterations in
    lung carcinoma from the VA National Precision Oncology Program. Semin Oncol.
    2022;49(3-4):265-274. doi:10.1053/j.seminoncol.2022.06.014
  4. Cascone T, Awad MM, Spicer JD, et al; for the CheckMate 77T Investigators.
    Perioperative Nivolumab in Resectable Lung Cancer. N Engl J Med.
    2024;390(19):1756-1769. doi:10.1056/NEJMoa2311926
  5. Wakelee H, Liberman M, Kato T, et al; for the KEYNOTE-671 Investigators.
    Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer. N Engl J
    Med. 2023;389(6):491-503. doi:10.1056/NEJMoa2302983
  6. Heymach JV, Harpole D, Mitsudomi T, et al; for the AEGEAN Investigators.
    Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. N Engl J
    Med. 2023;389(18):1672-1684. doi:10.1056/NEJMoa2304875
  7. Duncan FC, Al Nasrallah N, Nephew L, et al. Racial disparities in staging, treatment,
    and mortality in non-small cell lung cancer. Transl Lung Cancer Res. 2024;13(1):76-
    94. doi:10.21037/tlcr-23-407
References
  1. Tehzeeb J, Mahmood F, Gemoets D, Azem A, Mehdi SA. Epidemiology and survival
    trends of lung carcinoids in the veteran population. J Clin Oncol. 2023;41:e21049.
    doi:10.1200/JCO.2023.41.16_suppl.e21049
  2. Moghanaki D, Taylor J, Bryant AK, et al. Lung Cancer Survival Trends in the Veterans
    Health Administration. Clin Lung Cancer. 2024;25(3):225-232. doi:10.1016/j.
    cllc.2024.02.009
  3. Jalal SI, Guo A, Ahmed S, Kelley MJ. Analysis of actionable genetic alterations in
    lung carcinoma from the VA National Precision Oncology Program. Semin Oncol.
    2022;49(3-4):265-274. doi:10.1053/j.seminoncol.2022.06.014
  4. Cascone T, Awad MM, Spicer JD, et al; for the CheckMate 77T Investigators.
    Perioperative Nivolumab in Resectable Lung Cancer. N Engl J Med.
    2024;390(19):1756-1769. doi:10.1056/NEJMoa2311926
  5. Wakelee H, Liberman M, Kato T, et al; for the KEYNOTE-671 Investigators.
    Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer. N Engl J
    Med. 2023;389(6):491-503. doi:10.1056/NEJMoa2302983
  6. Heymach JV, Harpole D, Mitsudomi T, et al; for the AEGEAN Investigators.
    Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. N Engl J
    Med. 2023;389(18):1672-1684. doi:10.1056/NEJMoa2304875
  7. Duncan FC, Al Nasrallah N, Nephew L, et al. Racial disparities in staging, treatment,
    and mortality in non-small cell lung cancer. Transl Lung Cancer Res. 2024;13(1):76-
    94. doi:10.21037/tlcr-23-407
Publications
Federal Practitioner
Publications
Federal Practitioner
Topics
Oncology
Lung Cancer
Article Type
Article
Display Headline

Lung Cancer: Mortality Trends in Veterans and New Treatments

Display Headline

Lung Cancer: Mortality Trends in Veterans and New Treatments

Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Eyebrow Default
SLIDESHOW
Gate On Date
Tue, 03/18/2025 - 15:03
Un-Gate On Date
Tue, 03/18/2025 - 15:03
Use ProPublica
CFC Schedule Remove Status
Tue, 03/18/2025 - 15:03
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Article Slideshow Optional Introduction

The annual incidence rate of lung cancer among veterans is substantial and increasing, tripling from 2000 to 2017; historically, it was largely due to higher rates of smoking.1 In recent years, the VHA has aimed to improve survival rates of patients with lung cancer across all disease stages and racial/ethnic groups.2  These efforts include providing increased screening, molecular testing, and access to targeted therapies; adopting advanced surgical and biopsy techniques; and implementing nurse navigators to guide care.2

Veterans often have lung cancers that are strongly associated with smoking, which are less likely to harbor specific driver mutations such as EGFR or ALK alterations. This can limit the use of targeted therapies specifically designed for these mutations.1,3 However, newly developed immunotherapy agents, which do not rely on the presence of driver mutations, have shown significant efficacy in patients with non-small cell lung cancer (NSCLC), particularly in cases with high PD-L1 expression.4-6

Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
survey writer start date
Tue, 03/18/2025 - 15:03
Slide Media